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Abstract
Fluoroquinolones are antibacterial drugs that inhibit DNA Gyrase and Topoisomerase IV. These essential enzymes facilitate
chromosome replication and RNA transcription by regulating chromosome supercoiling. High-level resistance to
fluoroquinolones in E. coli requires the accumulation of multiple mutations, including those that alter target genes and
genes regulating drug efflux. Previous studies have shown some drug-resistance mutations reduce bacterial fitness, leading
to the selection of fitness-compensatory mutations. The impact of fluoroquinolone-resistance on bacterial fitness was
analyzed in constructed isogenic strains carrying up to 5 resistance mutations. Some mutations significantly decreased
bacterial fitness both in vitro and in vivo. We identified low-fitness triple-mutants where the acquisition of a fourth resistance
mutation significantly increased fitness in vitro and in vivo while at the same time dramatically decreasing drug
susceptibility. The largest effect occurred with the addition of a parC mutation (Topoisomerase IV) to a low-fitness strain
carrying resistance mutations in gyrA (DNA Gyrase) and marR (drug efflux regulation). Increased fitness was accompanied by
a significant change in the level of gyrA promoter activity as measured in an assay of DNA supercoiling. In selection and
competition experiments made in the absence of drug, parC mutants that improved fitness and reduced susceptibility were
selected. These data suggest that natural selection for improved growth in bacteria with low-level resistance to
fluoroquinolones could in some cases select for further reductions in drug susceptibility. Thus, increased resistance to
fluoroquinolones could be selected even in the absence of further exposure to the drug.
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Introduction
Fluoroquinolones are potent antibacterial drugs [1] that bind to
bacterial type II topoisomerases (DNA gyrase and topoisomerase
IV) when they are in complex with DNA. The drugs inhibit
chromosome re-ligation after enzyme-mediated cleavage [2].
Fluoroquinolones are effective against many bacteria including
invasive E. coli, but resistance is increasing with 28 of 29 countries in
Europe reporting a significant rise between 2001–2007 [3]. The
rapid increase is surprising because clinically relevant levels of
resistance in E. coli require multiple genetic changes, including
mutationsalteringtopoisomerasesandup-regulatingdrugefflux[4],
changes that are associated with reduced bacterial fitness in vitro and
in vivo [5–7]. Inappropriate use of fluoroquinolones, or co-selection
of resistant bacteria with the use of other antimicrobial drugs [8]
may be factors driving the increase in resistance but these may not
be the sole causes [9]. For example, resistant isolates of E. coli
increased from ,7–19% between 2001 and 2007 in the UK [3],
while outpatient fluoroquinolone use remained unchanged from
1997–2003 [9]. To develop an effective strategy to restrict the
increase in resistance frequency will require that we have a full
understanding of the factors driving the increase. The aim of this
paper was to investigate whether selection for improved fitness in
bacteria might itself be a factor promoting increased resistance.
The fitness costs of drug resistance can be reduced by selection
of low-cost mutations or by the accumulation of secondary fitness-
compensating mutations that do not reduce resistance. During
experimental evolution of clinical isolates of E. coli for decreased
susceptibility to fluoroquinolones most lineages (16/18) suffered
reduced growth competitiveness after only two or three selection
steps [5]. However, lineages selected for further decreases in
susceptibility were occasionally associated with a relative restora-
tion of fitness [5]. A similar reversal was noted in some constructed
strains of Streptococcus pneumoniae carrying one or two resistance
mutations [10]. These data suggested that some resistance
mutations might be selected because they decrease susceptibility
to the drug and simultaneously reduce the fitness costs associated
with existing resistance mutations. No cause for the phenomenon
has been demonstrated, and it’s relevance to bacterial fitness in vivo
in not clear. To examine the phenomenon we constructed isogenic
strains carrying various combinations of five resistance mutations
found commonly in fluoroquinolone-resistant clinical E. coli, and
measured their drug-susceptibility and fitness. The relationships
between the number of resistance mutations and bacterial fitness
were complex and the addition of a resistance mutation was shown
in some cases to improve bacterial fitness. These findings have
implications for the evolution of fluoroquinolone resistance in the
absence of antibiotic exposure.
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Resistance and fitness in clinical isolates: the paradox
The E. coli urinary tract infection isolate C1186 [4] is highly-
resistant to fluoroquinolones (MIC for ciprofloxacin $32 mg/ml)
and carries resistance mutations altering topoisomerases (gyrA
Ser83RLeu, Asp87RAsn; parC Ser80RIle), and up-regulating
drug efflux (marOR small deletion, and amino acid substitution;
acrR IS1 insertion). These 5 mutations are typical of highly
resistant clinical isolates [4]. C1186 has a growth rate similar to a
laboratory wild-type. Thus, these resistance mutations may
individually be low-cost, as found for some rifampicin-resistant
patient isolates [11,12] or the strain may carry additional fitness-
compensatory mutations [7]. A third possibility is that some
resistance mutations reduce existing fitness costs while simulta-
neously decreasing susceptibility to the drug. This last possibility is
highly relevant to the multi-step nature of fluoroquinolone-
resistance development. We constructed 28 isogenic derivatives
of the wild-type MG1655, each mimicking in part the complex
resistance genotype of C1186 (Table 1). Mutations were initially
isolated spontaneously (gyrA, parC) or constructed by l-red
recombineering (DmarR, DacrR) and then separately introduced
into MG1655 by P1 transduction. The gyrA and parC mutations
were transduced by selection for a linked genetic marker
(introduced using l-red recombineering, see Materials and
Methods) and at least 20 transductants of each cross were
subsequently screened by phenotype (MIC) and DNA sequencing
for the linked mutation. In every case only two phenotypic and
genotypic classes were found, showing that the gyrA and parC
mutations were not associated with other mutations.
Susceptibility of isogenic mutant strains
MIC for ciprofloxacin was measured for each strain (Table 1).
The margin of error of MIC values is 61 half-doubling step.
Accordingly, any change that is at least 2-fold is significant. Single
mutations in gyrA, S83L and D87N, increased MIC 24-fold and
16-fold respectively. Knockout mutations in marR and acrR
increased MIC only 2–3-fold, while the substitution S80I in parC
had no effect on MIC. Double mutation combinations had MIC’s
that were 8–64-fold wild-type level, with the combination
DmarR+DacrR having the smallest increase. Certain combinations
with parC were not tested because in E. coli parC mutations only
selected after the prior occurrence of a mutation in gyrA. Triple
mutation combinations have MIC’s that were 31–2000-fold wild-
type level. Most strains with three resistance mutations (5/9), and
all strains with 4 or 5 mutations had MIC’s above the 1 mg/ml
breakpoint that defines clinical resistance in Europe [13]
equivalent to 64-fold wild-type MIC in these strains. On average
there was a positive correlation between the number of resistance
mutations carried by a strain and the MIC for ciprofloxacin
(Figure 1).
Fitness of isogenic resistant strains
The 28 mutant strains were tested in growth competitions
against wild-type to measure their Malthusian fitness [14,15] as a
function of the resistance mutations they carried (Table 1). The
fitness value associated with having either one or two resistance
mutations ranged from ,1 down to 0.82 per generation. Some
single mutations (gyrA S83L, gyrA D87N, and parC S80I) were
statistically neutral whereas others (DmarR and DacrR) caused a
significant reduction in fitness (0.83 and 0.91 per generation,
respectively). Strains carrying three resistance mutations had
fitness values that ranged from ,1 down to as low as 0.60, with 8/
9 strains suffering a fitness deficit of $5% per generation.
Interestingly, the addition of a fourth resistance mutation to these
strains restricted the minimum fitness value to 0.66 per generation,
higher than that measured with three mutations (Figure 1). When
all five resistance mutations were present the fitness value was
0.68. Thus, some strains carrying 4 or 5 resistance mutations have
a higher fitness than some strains carrying only 3 mutations. The
major negative effect on fitness was associated with the presence of
the marR and acrR mutations. Thus, fitness did not decrease as a
simple function of the number of resistance mutations, but instead
depended critically on the nature of those mutations.
For some strains an increased MIC correlates with
improved fitness
In general the addition of a resistance mutation to a strain was
either neutral with respect to MIC and fitness, or it caused an
increased MIC and / or decreased fitness (Figure 1, Table 1).
Across all the strains constructed decreased fitness was very
strongly associated with the presence of one or both efflux
mutations. In contrast, strain LM693 (gyrA S83L, D87N; parC
S80I) has high level resistance (MIC 32) with no significant
reduction in fitness relative to the wild-type (Table 1). LM693
shows that it is possible to evolve high level resistance with no, or
minimal, fitness costs. However, mutations up-regulating drug
efflux are highly relevant to resistance evolution because they arise
at a rate hundreds of times higher than mutations in the structural
genes for topoisomerases. This is because the genetic target for
knockout mutations in efflux regulating genes is much larger than
the target for the specific amino acid substitutions required in
topoisomerase genes. Thus, even though, as shown here, efflux
mutations are fitness-costly and contribute relatively small
increases in resistance, they occur very frequently, and are found
in many resistant clinical isolates [4]. For three low-fitness strains,
each carrying three resistance mutations including a marR
mutation, the addition of an extra resistance mutation increased
both MIC and fitness: LM695RLM707; LM882RLM707; and
LM871RLM707 (Figure 1 and Table 1). In these strains the
added mutation affected gyrA or parC. The increased fitness was
statistically significant (Students t-test, two-tailed, p,0.05) in two
of the three cases, LM695.LM707 and LM882RLM707
(Table 2). The robustness of these results was verified by
Author Summary
The increasing frequency of human pathogens resistant to
important classes of antibiotics poses a serious and
growing challenge for medicine and society. We need
improved strategies to reduce the rate of resistance
development, for established and novel drugs, based on
knowledge of the factors that drive the increase in
resistance. Resistance to fluoroquinolones in most bacteria
develops via a series of sequential genetic changes
affecting several different genes. These are selected and
enriched in bacterial populations by exposure to the drug.
Relevant factors driving this increase include overuse, and
inappropriate use, of these drugs. In this paper we show
that mutant bacteria with low-level resistance (not itself a
problem to treat with standard drug doses) can evolve by
natural selection (for improved growth rate) to acquire
mutations that dramatically increase their level of drug
resistance. This means that we may need to consider how
to reduce inappropriate drug use that can enrich for
bacteria with low-levels of resistance, because at that
stage some of the mutant bacteria in the population may
continue to evolve higher level resistance even in the
absence of any further drug exposure.
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measuring their MIC and fitness values. No significant differences
were found from the original values. In addition, we tested these
critical strains by de-construction experiments: replacing gyrA and/
or parC mutations with equivalent wild-type genes and determin-
ing that the MIC and fitness values of the de-constructed strains
were as expected. Based on these two experiments, re-constuction,
and de-construction, we are confident that the isogenic strains do
not carry any additional mutations affecting MIC or fitness. Thus,
the addition of a single resistance mutation can increase growth
fitness by 5–10% per generation and simultaneously increase MIC
more than 40-fold (Table 2).
Fitness in a mouse infection model
The data in the previous section showed that the addition of a
fourth resistance mutation to either LM695 or LM882 could
significantly increase competitive growth fitness measured in vitro.
This result would be more interesting from a clinical viewpoint if
the measured increase in fitness was not exclusively an in vitro
phenomenon. To test this competition experiments were made in
a mouse UTI infection model [16]. Each of the strains (LM695,
LM883, and LM707) was competed against the isogenic wild-type
in the mouse model and relative fitness expressed as a competitive
index (C.I.).Three different measures of C.I. could be obtained in
this model: from the urine; the bladder; and the kidneys. For each
strain and tissue there was a clear positive correlation between
relative fitness in vivo and in vitro (Figure 2). Thus, the relative order
of fitness values of these strains, initially measured in vitro, was
confirmed in the physiologically more complex in vivo environ-
ments.
Fitness compensation and changes in DNA supercoiling
The marR mutation makes the single largest contribution to loss
of fitness in these 28 strains (Table 1). The marR mutation alone
Table 1. Genotypes, susceptibility, and fitness of isogenic strains.
Strain gyrA1 gyrA2 parC marR acrR MIC
b Fitness (SD)
c P
d N
e
MG1655 - - - - - 0.016 1.00 (0.01) - 5
LM378 S83L - - - - 0.38 1.01 (0.03) 0.37 6
LM534 - D87N - - - 0.25 0.99 (0.03) 0.57 7
LM792 - - S80I - - 0.016 0.99 (0.01) 0.59 5
LM202 - - - D - 0.032 0.83 (0.03) ,0.0001 5
LM351 - - - - D 0.047 0.91 (0.02) ,0.0001 5
LM625 S83L D87N - - - 0.38 0.97 (0.03) 0.04 8
LM862 S83L - S80I - - 1 0.98 (0.03) 0.18 6
LM421 S83L - - D - 1 0.86 (0.03) ,0.0001 5
LM647 S83L - - - D 0.5 0.95 (0.04) 0.02 11
LM1124 - D87N S80I - - 0.38 1.02 (0.02) 0.04 8
LM538 - D87N - D - 1 0.83 (0.03) ,0.0001 5
LM592 - D87N - - D 0.38 0.92 (0.03) 0.0001 10
LM367 - - - DD 0.125 0.82 (0.04) ,0.0001 5
LM693 S83L D87N S80I - - 32 1.01 (0.02) 0.48 13
LM695 S83L D87N - D - 0.75 0.79 (0.03) ,0.0001 10
LM691 S83L D87N - - D 0.75 0.93 (0.03) 0.0002 13
LM871 S83L - S80I D - 6 0,86 (0.03) ,0.0001 10
LM873 S83L - S80I - D 3 0.92 (0.04) 0.0005 10
LM882 - D87N S80I D - 0.75 0.84 (0.05) ,0.0001 14
LM1125 - D87N S80I - D 0.5 0.95 (0.01) ,0.0001 8
LM709 S83L - - DD 1.5 0.78 (0.04) ,0.0001 5
LM595 - D87N - DD 1.5 0.60 (0.09) ,0.0001 10
LM701 S83L D87N - DD 2 0.66 (0.07) ,0.0001 10
LM707 S83L D87N S80I D - 32 0.89 (0.03) ,0.0001 10
LM703 S83L D87N S80I - D 32 0.94 (0.03) 0.0009 14
LM875 S83L - S80I DD 8 0.71 (0.04) ,0.0001 5
LM878 - D87N S80I DD 2 0.72 (0.05) ,0.0001 10
LM705 S83L D87N S80I DD 32 0.68 (0.07) ,0.0001 5
aGenotype. Strains are isogenic to MG1655 and carry only the mutations shown.
bMIC for ciprofloxacin (mg/ml).
cFitness. Mean fitness per generation, relative to wild-type, SD, standard deviation (within parentheses) measured in pair wise competition against the isogenic wild-
type (DaraBC).
dP. Statistical significance of difference in fitness relative to the wild-type (Students t-test (95% confidence limit, two-tailed P-value).
eN. Number of independent competition experiments on which the fitness value is based.
doi:10.1371/journal.ppat.1000541.t001
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strains carrying marR is 0.76 (SD 0.08). MarR protein regulates,
directly and indirectly, transcription of many genes [17] and the
reduction in fitness associated with loss of function mutations in
mar is most likely because of disruption of gene regulation. This
suggests a possible mechanism of fitness compensation associated
with resistance mutations in topoisomerase genes. Thus, some
topoisomerase mutations that alter chromosomal supercoiling
levels may partially restore expression of growth-limiting gene(s)
regulated by mar, reversing the fitness deficit. This hypothesis
predicts that the improvement in fitness measured in
LM695RLM707 should be associated with a change in global
supercoiling level. This was tested by electrophoresis of pUC18
and pUC19 plasmids purified from MG1655, LM695 and LM707
in chloroquine-agarose gels [18]. With this method we were
unable to detect differences in plasmid topoisomer patterns (data
not shown). We also tested for differences in supercoiling using a
reporter gene assay [19,20]. This was done by introducing
plasmids carrying a luciferase reporter gene fused to each of two
different promoters (ptopA and pgyrA) whose expression is sensitive
to, respectively, increased or decreased supercoiling levels [20]. In
this assay the ratio (ptopA /p gyrA) of reporter gene expression from
Figure 1. Resistance and fitness of constructed strains. For the
wild-type and each of the 28 constructed isogenic strains the MIC for
ciprofloxacin (part A) and the relative fitness per generation in in vitro
growth competition (part B) is shown as a function of the number of
resistance mutations per strain. Each diamond symbol represents one
strain. In some cases more than one symbol occupies the same space.
Strain identification numbers are shown for four strains of particular
interest (Table 2).
doi:10.1371/journal.ppat.1000541.g001
Table 2. Single mutations decrease drug susceptibility and
increase fitness.
Strain gyrA1 gyrA2 parC marR MIC
b Fitness (SD)
c P
d N
e
LM695 S83L D87N - D 0.75 0.79 (0.03) ,0.0001 10
LM707 S83L D87N S80I D 32 0.89 (0.03) 10
LM882 - D87N S80I D 0.75 0.84 (0.05) 0.014 14
LM707 S83L D87N S80I D 32 0.89 (0.03) 10
LM871 S83L - S80I D 6 0.86 (0.03) 0.05 10
LM707 S83L D87N S80I D 32 0.89 (0.03) 10
aGenotype; All strains are isogenic to MG1655 and carry only the mutations
shown.
bMIC for ciprofloxacin (mg/ml).
cFitness; Mean fitness per generation (relative to wild-type). SD, standard
deviation (within parentheses) measured in pair wise competition against the
isogenic wild-type.
dP; Significance of fitness difference between the strains in each pair, (Students
t-test, two-tailed P-value).
eN; Number of independent competition experiments on which the fitness
value is based.
doi:10.1371/journal.ppat.1000541.t002
Figure 2. Fitness in vitro as a function of fitness in vivo in a
mouse UTI model. Samples from urine, kidney, and bladder are
illustrated with black diamonds, triangles, and squares, respectively. The
addition of one extra resistance mutation to either LM695, or LM882
created LM707, with increased fitness in vitro and in vivo and an
increase in MIC for ciprofloxacin from 0.75 to 32 mg/ml.
doi:10.1371/journal.ppat.1000541.g002
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is a measure of the relative level of negative supercoiling in
isogenic strains [19,20]. Qsc was 2.9 (SD 0.7) for MG1655 (n=6),
2.6 (SD 0.7) for LM695 (n=12), and 3.6 (SD 1) for LM707
(n=13). In this assay neither of the mutant strains differed
significantly from the wild-type, but LM695 and LM707 differed
significantly from each other (P value 0.01, Students t-test, two
tailed). From the expression data it was clear that the major cause
of this difference in Qsc between LM695 and LM707 was due to a
25% decrease in expression from the gyrA promoter construct in
LM707 relative to LM695. Thus the introduction of the parC S80I
mutation to make strain LM707 caused a significant increase in
the Qsc, coincident with the improvement in fitness. Although we
cannot explain the absence of an effect in the chloroquine-agarose
assay, the reporter gene assay suggests that some changes in
chromosomal supercoiling associated with the acquisition of
topoisomerase mutations may provide a mechanism linking
bacterial fitness and decreased susceptibility to fluoroquinolones.
However, an alternative explanation is that the combination of
mutations in LM707 reduces expression of gyrA by a mechanism
that does not change global supercoiling levels, and that it is a
consequence of the reduced expression of gyrA that causes the
increase in growth fitness. Additional experiments will be required
to distinguish between these models.
Selection of improved-fitness highly-resistant mutants
In the sections above it was shown that the transfer of the parC
S80I mutation into LM695 increased its MIC for ciprofloxacin
and its competitive growth fitness versus the wild-type. This
predicted that the resulting constructed strain, LM707, should
outcompete LM695 in a head-to-head competition, and also
raised the following questions: (i) could a mutant with an increased
MIC for ciprofloxacin and a higher growth fitness be selected
spontaneously from LM695 in the absence of drug; and (ii) would
such a mutant be exclusively associated with of the acquisition of
the parC S80I mutation. These predictions and questions were
addressed experimentally. First, in head-to-head growth compe-
tition experiments in LB medium with no drug, LM707 (four
resistance mutations) outcompeted LM695 (three resistance
mutations), gaining ,8% per generation, in good agreement with
the relative differences in growth fitness of each strain versus the
wild-type (Table 1). Second, 96 independent lineages of LM695
were grown in rich medium in the absence of drug for 4 growth
cycles. Each growth cycle was inoculated with 2610
6 cfu and
grown to a total of 2610
8 cfu (,7 generations per growth cycle) in
a volume of 200 mL. An aliquot of 5610
6 cfu from each lineage
was tested, after the completion of 2, 3, and 4 cycles of growth, for
the presence of resistant mutants on solid medium (3 mg/mL
ciprofloxacin, 46MIC). Growth of LM695 is completely inhibited
on 3 mg/mL ciprofloxacin and the spontaneous mutation rate to
resistance on this media, measured in fluctuation tests, is 2610
28.
Accordingly, we expected that virtually none of the 96
independent lineages would contain a resistant mutant at the
initiation of the experiment, but that a small number of resistant
mutants would arise in each lineage during each growth cycle. If
these mutants out-competed the parental LM695 they would be
expected to increase relative to LM695, and thus have a greater
probability of being transferred to the next growth cycle. The
number of lineages from which resistant mutants were obtained
was found to increase with successive growth cycles: from 2/96
(cycle 2)R8/96 (cycle 3)R15/96 (cycle 4). Because the spontane-
ous mutation rate to resistance (2610
28) if much lower than the
number of cells being tested from each lineage (5610
6) it is very
unlikely that these mutants arose on the selective media. Instead,
the most reasonable conclusion is that the resistant mutants arose
spontaneously and randomly during the growth of lineages in the
absence of drug and were enriched because they out-competed the
parent population. Three random drug-resistant mutants were
chosen from independent lineages and tested by DNA sequencing
for the presence of mutations in gyrA and B,i nparC and E, and in
marR and acrR. In each case the mutations originally present in
LM695 were confirmed and in addition each of the mutants was
found to have acquired a new mutation in parC (S80R in two cases,
and E84K in one case). The MIC CIP of each of the mutants had
increased from 0.75 to .32 mg/mL, and the exponential doubling
time in rich medium had increased significantly, by ,10% per
generation (Table 3). Thus, the selection of a spontaneous parC
mutation in LM695 decreased its susceptibility to ciprofloxacin
and increased its growth rate. From these experiments we
concluded that the phenotypes generated directly by strain
construction (LM695RLM707; reduced drug susceptibility and
increased growth fitness) could also be generated by a variety of
spontaneous mutations, and that the growth advantage phenotype
could be enriched by growth selection in the absence of drug.
Discussion
A set of 28 isogenic E. coli strains was constructed and used to
measure the relationship between the accumulation of fluoroquin-
olone resistance mutations, drug susceptibility, and growth fitness.
The question was whether the accumulation of up to five
resistance mutations, commonly found in resistant clinical isolates,
would progressively reduce bacterial fitness. Most of the published
data on the relationship between drug resistance and bacterial
fitness would predict two possibilities: (i) that these mutations
would cause little or no fitness cost, explaining their high
frequency among resistant isolates; or (ii) that their accumulation
would cause a progressive decrease in bacterial fitness, and require
additional fitness-compensating mutations to restore fitness [6,7].
The data from this study support, in part, each of these scenarios
(Table 1, and Figure 1). However, they also revealed, for some
combinations of resistance mutations, a positive relationship
between reduced drug-susceptibility and increased bacterial
fitness. This positive relationship could be another driving force
in the development of increased resistance to these antibacterial
drugs. Although this may be the first demonstration in bacteria
that in the absence of an antimicrobial, selection can increase
resistance to that antimicrobial, a similar phenomenon has been
reported for HIV resistance to a protease inhibitor [21]. Thus, the
phenomenon described here may have a broad biological
significance.
Table 3. Selection of LM695 to faster growth and increased
MIC.
Dt
a P value
b Mutation
c MIC
d
LM695 23.060.7 - - 0.75
LM1179 20.861.0 ,0.0001 parC S80R .32
LM1198 20.860.5 ,0.0001 parC S80R .32
LM1199 21.260.7 ,0.0001 parC E84K .32
aDt; doubling time in min in LB medium at 37uC.
bP-value; Significance of the difference in generation time relative to LM695, the
parental strain, Students t-test for independent samples, n=10 for each strain.
cMutation; Identity of the new mutation identified in each evolved strain.
dMIC; for ciprofloxacin (mg/ml) of LM695 and each of the evolved strains.
doi:10.1371/journal.ppat.1000541.t003
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1. Some resistance mutations, individually or when incorporated
in an already mutant strain, reduced drug susceptibility without
significantly reducing fitness. Other mutations were individu-
ally or in combination associated with significant fitness costs.
This suggests that selection for low-cost mutations, and/or
compensating mutations could be selective forces determining
the frequency of particular mutations individually or in
combination. The marR mutation had the largest negative
effect on fitness.
2. In some cases, the addition of a resistance mutation to an
already low-fitness mutant strain caused a further reduction in
drug susceptibility and an increase in relative fitness (Figure 3).
The improved fitness of these strains was also measured in vivo.
Thus, particular combinations of resistance mutations could
potentially be selected either because they reduce drug
susceptibility, and/or because they improve the relative fitness
of the mutant strain.
3. The positive effect of these combinations of resistance
mutations on fitness was accompanied by a significant change
in the level of gyrA expression measured in a reporter gene assay
of supercoiling. This suggests that reversing the negative effects
of the marR mutation on gene regulation may be a mechanism
for expression of the phenotype.
4. Growth of a low-fitness strain in the absence of drug selected
for mutants with increased growth fitness and reduced drug
susceptibility. Because each culture was initiated with a pure
clone, these mutants must have arisen spontaneously during the
growth of the cultures and been selected because they had a
competitive advantage. This showed that the phenotype could
be selected in the absence of drug, and that it was not limited
to a unique combination of mutations.
Molecular details of how particular parC and gyrA mutations
together improve the fitness of a resistant strain with a marR
mutation are beyond the scope of this study but we can suggest
the outlines of a model. Growth rate depends on the rate of
transcription regulated in accordance with physiological demands
[22]. The MarR protein regulates, directly and indirectly, the
transcription of many genes [17] and it is probable that the severe
reduction in fitness associated with DmarR (Table 1) is because it
causes inappropriate patterns of transcription regulation. We
suggest that specific mutant forms of DNA gyrase and topoisom-
erase IV, possibly by acting in concert to influence the level of
superhelicity in DNA, restore appropriate levels of gene expression
at some loci where the loss of MarR regulation has a negative
impact on growth rate [23,24].
The particular gyrA and parC resistance mutations studied here
are clinically relevant, being among the most common found in
fluoroquinolone-resistant clinical isolates of E. coli [4]. Among 30
resistant UTI isolates analyzed: 30/30 had the gyrA S83L
mutation; 18/30 had the double mutation gyrA S83L, D87N;
22/30 had the parC mutation S80I; and 15/30 had the triple
combination gyrA S83L, D87N, parC S80I (23/30 had some form
of triple mutation combination including other substitutions at
position 87 of gyrA and/or position 80 of parC). Thus, the
combination of target mutations studied here is typical of resistant
clinical isolates. As measured by organic solvent tolerance, drug
efflux was phenotypically up-regulated in 15/30 of these resistant
isolates, associated in most cases with mutations in acrR and/or
marOR [4]. The observed frequency of the efflux phenotype is very
low relative to the frequency of specific gyrase and topoisomerase
mutations in the same isolates, and given the much higher
expected probability of mutations that knock out the function of
efflux regulator genes it suggests selection against such mutations.
This under-representation is consistent with our finding that
mutations up-regulating efflux pumps carry significant fitness
costs. The growth fitness of clinical isolates cannot be meaningfully
compared with the data presented in this paper, in part because
clinical isolates are not isogenic, and in part because clinical
isolates will already have evolved to ameliorate the fitness costs, if
any, associated with their resistance determinants. We believe that
our data provide an insight into the likely initial effects on relative
fitness and drug susceptibility of different pathways of resistance
development. In particular, that one consequence of a following a
high-probability but low-fitness evolutionary pathway may be that
one or more steps may be driven by selection for increased fitness
in the absence of drug exposure.
How fluoroquinolone resistance evolves in nature will depend
on the genotype being selected and on the selective environment
[25] but it is likely include mutational steps that reduce bacterial
fitness. Bacteria that progress down an evolutionary path with
reduced fitness relative to a competing population may be driven
to extinction, or may, given the opportunity by mutation,
acquire a change that increases their relative fitness thus
improving their chances of survival. Evolutionary paths that
could be taken on the road to extinction or antibiotic resistance
are outlined in Figure 3. The low-fitness mutants LM695 and
LM882 each have MICs that lie under the resistance breakpoint
for ciprofloxacin [26,27]. Such mutants are at a critical stage in
resistance development: having low fitness they may be driven to
extinction by natural selection; being under the resistance
breakpoint they may avoid detection in a clinical setting;
however, they are, as shown here, only one mutational step
away from a high-level resistance phenotype with increased
fitness, without additional exposure to the drug. The magnitude
of these co-selected changes in fitness and susceptibility are
significant (Table 2). These data argue in favor of testing anti-
mutant dosing strategies, or other measures that could prevent
the enrichment of low-level resistant mutants [28].
Figure 3. A general model illustrating evolutionary paths for a
lineage under antibiotic selection. Mutual compensation, the
acquisition of a mutation that simultaneously improves fitness and
reduces susceptibility to the antibiotic, is the pathway presented in this
manuscript.
doi:10.1371/journal.ppat.1000541.g003
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Strains and growth conditions
C1186 is a multiply mutant fluoroquinolone resistant UTI
isolate previously described [4]. E. coli K12 MG1655 wild-type was
the starting strain for all constructions (Table 1). Liquid growth
medium was Luria broth (LB) while solid medium was Luria-
Bertani agar (LA). Strains were grown at 37uC. Ciprofloxacin
(Bayer HealthCare AG, Wuppertal, Germany) was dissolved in
0.1 M NaOH at 100 mg/mL then further diluted in LA in
selective plates.
MIC determinations
MIC was determined by Etest (AB BIODISK, Solna, Sweden)
on Mueller-Hinton agar plates incubated for 16 to 18 h at 37uC
with quality control reference strains [4] as recommended by the
Clinical and Laboratory Standards Institute (www.clsi.org).
Selection of mutations and strain construction
Spontaneous resistance mutations in gyrA and parC were selected
sequentially in E. coli MG1655 in LB with ciprofloxacin at 2–8-fold
MIC and mutations were identified by DNA sequencing.
Individual mutations were always moved into a clean genetic
background (MG1655) after initial selection. Deletion-replacement
mutations in marR, acrR, yfaH, metC and araB were made by l-red
recombineering [29] in NC397 (a Lac
+ Nad
+ derivative of DY329)
using PCR amplified linear DNA from pCP16 with an FRT-
bounded Tc
R cassette [30]. The PCR reaction protocol was 95uC
5 min followed by 30 cycles of 95uC 15 sec, 55uC 20 sec, 72uC
240 sec. PCR primer sequences with details of the deletion-
replacement boundaries are shown in Supporting Information
(Table S1).
Construction of isogenic strains
Isogenic derivatives of MG1655 were constructed by phage P1-
mediated transduction. Transduction of the deletion-replacement
mutations in marR and acrR was selected directly on LA+Tc. When
transducing the gyrA and parC mutations selection was made for the
linked markers, yfaH,.Frt::Tc
R::Frt and metC,.Frt::Tc
R::Frt,
each ,10 kb from gyrA and parC, respectively. Note that we are
using the symbol ,. to indicate a replacement generated by l red
homologous recombination technology. After transduction the Tc
R
marker was removed by Flp-catalyzed excision expressed following
transformation with pCP20 [30]. All strain constructs were
confirmed by DNA sequencing.
Growth competition assays
LM347 (DaraB,.FRT) was used as the standard wild type
strain in growth competitions against which each of the
constructed mutant strains was competed. This strain was tested
against its parent MG1655 showing that the DaraB mutation was
neutral (relative growth rate 1.00260.005). To support statistical
analysis each competition was tested in at least 5 independent
experiments (Table 1). To initiate growth competitions, each strain
was grown in LB at 37uC 12 h, mixed in a 1:1 ratio, diluted 10
23
into LB, then grown 23 h to complete a growth cycle. Each
successive growth cycle was initiated by diluting the mixture 10
23
into LB. Each competition experiment (4 cycles) was made the
number of times indicated in Table 1. For some low-fitness strains
such as LM595 the mutant population became too low to detect
after the second or third cycle of competition. After the initial
mixing, and after each growth cycle, appropriate dilutions of the
mixture were plated onto MacConkey agar plates containing 1%
arabinose. Plates were incubated 37uC overnight. Red (ara
+) and
white (DaraB) colonies were scored. The change in the ratio of
mutant/wild-type was used to estimate the selection coefficient per
generation of each of the constructed strains according to the
formula: S=ln2 (mutant/wild-type) / generation [31]. Relative
fitness per generation with respect to the wild-type LM347 is
defined as S+1. Note that the fitness defects could be due to defects
at any stage of the growth cycle (lag, exponential, stationary
phase).
The ascending urinary tract infection model in mice
Relative bacterial fitness in vivo was measured using an
established urinary tract infection model [16]. Details, including
mouse strain and ethical permission, are given in Text S1.
Competitive index was calculated as the geometric mean of the
ratio of mutant/wild-type bacteria isolated from each organ (urine,
bladder, kidneys) of 8 mice per experiment, normalised to the ratio
at the time of inoculation.
Growth rate measurements
Exponential doubling times were calculated by measuring the
increase in optical density at 600 nm (OD600) at 10-min intervals,
using a BioscreenC machine (Oy Growth Curves Ab Ltd. Helsinki,
Finland).
Evolution of improved fitness mutants
The mutation rate of LM695 to resistance on LA+3 mg/mL
ciprofloxacin (CIP) is 2610
28 measured by fluctuation test.
Independent lineages were inoculated in 966200 mL wells, and
grown 24 h at 37uCt o,10
9 CFU/mL. 2 mL was transferred to
initiate a new growth cycle. 5 mL was plated on LA+3 mg/mL CIP
to assay for resistant mutants.
Supercoiling assay
The relative supercoiling degree was determined using a
published assay. The quotient of supercoiling, Qsc [19] is defined
as the ratio of luciferase activity from two different supercoiling
sensitive promoters, ptopA-luc, and, pgyrA-luc, [20]. Details are
given in Text S2.
Supporting Information
Table S1 Oligonucleotides used to amplify linear PCR frag-
ments for l-red recombineering
Found at: doi:10.1371/journal.ppat.1000541.s001 (0.03 MB
DOC)
Text S1 The ascending urinary tract infection model in mice.
Found at: doi:10.1371/journal.ppat.1000541.s002 (0.03 MB
DOC)
Text S2 Supercoiling assay.
Found at: doi:10.1371/journal.ppat.1000541.s003 (0.03 MB
DOC)
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